FDFT1 and uterine disorder: There is now a need for in vivo experiments, perhaps using intrauterine infusion of an FDFT1 inhibitor to increase farnesyl pyrophosphate and geranylgeranyl pyrophosphate, to confirm our present data and examine if isoprenoids can increase endometrial tolerance to pyolysin, in order to prevent postpartum uterine disease, such as metritis and endometritis.